Program Overview
This CME/CE program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option. Practical strategies for safely utilizing oncolytic viral therapies in clinical practice as well as best practices for engaging the interprofessional team will be relayed to the learner through an discussion-based format. This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis and expert perspectives through conference coverage educational programs.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, oncologists, and interprofessional healthcare clinicians responsible for the care of patients with metastatic melanoma.
Learning Objectives
- Understand the metastatic melanoma science, including patient screening, diagnostic criteria, and the mechanism of action of oncolytic viral therapeutics.
- Analyze evidence based medicine for combination therapies that apply oncolytic viral therapeutics to the treatment of metastatic melanoma.
- Incorporate communication strategies and patient education into individualized treatment plans to improve outcomes and the overall quality of life in patients with metastatic melanoma.
Faculty
Michael Postow, MD (Course Chair)
Medical Oncologist
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, New York
Charlotte Ariyan, MD, PhD
Surgical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Francesca Mistretta, BSN, RN, CMSRN
Memorial Sloan Kettering Cancer Center
New York, New York
